I have been working in the logistics sector for almost two decades. I have been into stock investing and macroeconomic analysis for almost a decade. Currently, I focus on ASEAN and NYSE/NASDAQ Stocks, particularly in banks, telco, logistics, and hotels. Since 2014, I have been trading on the PH stock market. I focus on banking, telco, and retail sectors. A colleague encouraged me to engage in the stock market as part of my portfolio diversification instead of putting all my savings in banks and properties. ...

New Found Gold Corp. (NFGC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual investors of ...

Canada Goose (GOOS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The p ...

Investors might want to bet on Astrana Health, Inc. (ASTH) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a c ...

Investors might want to bet on Cadence (CADE) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing e ...

公司评级与目标价调整 - Keybanc将Roku评级从"行业权重"上调至"增持" 目标价设定为115美元 主要基于公司预算和广告更新的潜在利好 [1] - Piper Sandler前一交易日将目标价从65美元上调至84美元 [1] 股价表现与交易动态 - 当日股价最高触及91.66美元 创2月以来新高 但涨幅收窄至0 8% 报89 33美元 [2] - 较4月低点52 43美元累计上涨70% 年内涨幅达19% [2] - 短期阻力位在90美元附近 空头回补可能突破该关口 [3] 空头头寸与期权数据 - 空头兴趣在过去两个报告期下降16 6% 但仍有767万股空头仓位 占流通股的6% [3] - 波动率指数(SVI)为41% 处于年度范围的第1百分位 显示期权市场对波动预期较低 [3]

Rhythm Pharmaceuticals, Inc. (RYTM) shares rallied 36.6% in the last trading session to close at $89. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.3% loss over the past four weeks.The stock rallied after the company announced positive top-line data from a phase II study evaluating its investigational oral melanocortin-4 receptor (MC4R) agonist, bivamelagon, in patients with acquired hypothalamic obesity. ...

股价表现与目标价分析 - Kennedy-Wilson(KW)近期股价收于7 46美元 过去四周涨幅达11 3% 华尔街分析师给出的平均目标价9 9美元隐含32 7%上行空间 [1] - 三个短期目标价区间为7 70-13 00美元 标准差2 76美元 最低目标价隐含3 2%涨幅 最高目标价隐含74 3%涨幅 标准差反映分析师预测分歧程度 [2] - 尽管共识目标价受投资者关注 但分析师设定目标价的能力和客观性长期受质疑 仅依赖该指标做投资决策可能带来负面影响 [3] 盈利预测与评级 - 分析师普遍上调KW盈利预测 修正趋势增强股价上涨预期 盈利预测修正与短期股价走势存在强相关性 [4][11] - Zacks共识预期显示当前年度EPS预测过去一个月上调245 5% 仅见正面修正无负面调整 [12] - KW目前获Zacks评级2级(买入) 位列4000多只股票前20% 该评级基于盈利预测相关四项因素 具备外部审计验证的可靠记录 [13] 目标价有效性研究 - 全球多所大学研究表明 目标价作为股票信息常误导投资者 实证显示分析师目标价鲜少准确预测股价实际走向 [7] - 华尔街分析师虽掌握公司基本面 但常因业务关系设定过度乐观目标价 覆盖股票的商业利益导致目标价虚高 [8] - 低标准差显示分析师对股价变动方向和幅度高度一致 虽不保证达到平均目标价 但可作为研究基本面驱动力的起点 [9] 投资建议框架 - 投资者不应完全忽视目标价 但仅凭此决策可能导致投资回报不佳 需保持高度怀疑态度 [10] - 尽管共识目标价可靠性存疑 但其暗示的价格变动方向仍具参考价值 结合盈利预测修正趋势更具指导意义 [14]

股价表现 - Vir Biotechnology股价在最近一个交易日飙升11.9%至5.93美元，成交量显著高于正常水平[1] - 过去四周该股累计下跌2.2%，此次上涨形成明显反转[1] - 同行业公司Opus Genetics同期上涨4.7%至1.11美元，过去一个月累计上涨3.9%[4] 研发进展 - 股价上涨源于投资者对tobevibart的乐观预期，该药物是公司唯一处于后期阶段的候选产品[2] - tobevibart与Alnylam的elebsiran联用，正在进行治疗慢性丁型肝炎的III期ECLIPSE 1注册研究[2] - 公司准备启动III期ECLIPSE 2研究，评估对bulevirtide治疗无应答患者的疗效[2] 财务预期 - 公司预计季度每股亏损0.74美元，同比改善27.5%[3] - 预计营收705万美元，同比增长128.8%[3] - 过去30天共识EPS预期维持不变，缺乏盈利预期上调趋势[4] 行业评级 - Vir Biotechnology在Zacks医疗-生物医学和遗传学行业排名第二(买入)[4] - 同行业Opus Genetics同样获得Zacks第二评级(买入)[5] - Opus Genetics预计季度每股亏损0.25美元，同比改善16.7%[5]

Toledo - Circa September 2020: Owens Corning Headquarters. Owens Corning develops and produces ... More insulation, roofing, and fiberglass composites.getty Uncertainty around the broader economic outlook continues to fuel market volatility.Navigating the noise requires a disciplined approach. By digging into the underlying financials, investors can uncover the true value of a stock – an essential skill for those looking to weather volatility, particularly with dividend-paying investments.A particularly ris ...